Trial composition
0 of 0 selected trial records include at least one phase value; 0 of 0 include a status value in the retained structured contract.
Not FDA-approved1,6Evidence: Limited human dataNot a peptideMuscle
Not a peptide: a protein, larger than a peptide, often looked up alongside peptides.
Follistatin is a natural protein that blocks myostatin, a signal that limits muscle growth. Follistatin-344 (FS344) is one of its forms. At hundreds of amino acids it is a protein under FDA’s definition, not a peptide.1,2,5 The human studies reviewed here tested a gene therapy carrying the FS344 gene, not the protein itself: two small trials, each in six people with a muscle-wasting disease, reported longer walking distances in most participants.3,4 No FDA approval is reported in the sources reviewed here, and follistatin-344 is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.1,6,8
| Substance type | Not a peptide. FDA’s substance registry records follistatin as a protein with a 315-amino-acid chain, and FDA’s 2020 rule defines a protein as a chain of more than 40 amino acids.1,2 |
|---|---|
| What it is | A form of follistatin, an activin-binding protein that FDA’s substance registry records with a 315-amino-acid chain.1,3 |
| FDA status | No FDA approval is reported in the sources reviewed here. FDA’s compounding safety-risk page does not list follistatin.1,6 |
| Human evidence | Two small uncontrolled or partly controlled gene-therapy trials, each in six people, that delivered the FS344 gene; no human studies of the protein itself are described in the sources reviewed here.3,4 |
| Evidence strength | Limited human data. The only cited human studies are small, short, uncontrolled, or incompletely reported, such as case series, pilot studies, or trials published only as a conference abstract whose methods and results cannot be checked. How this label is assigned |
Follistatin is a protein that binds activin and blocks myostatin. FDA’s substance registry records it as an activin-binding protein with a 315-amino-acid chain, and anti-doping researchers describe it as a myostatin-inhibiting protein.1,5
Follistatin-344, or FS344, is one of the forms produced by alternative splicing of the follistatin gene; researchers chose it for gene therapy to avoid binding to unintended sites.3
FDA’s 2020 rule defines a protein as a chain of more than 40 amino acids, so follistatin counts as a protein, not a peptide.1,2
Myostatin normally limits muscle growth. Follistatin is a potent myostatin antagonist, and animal studies delivering the follistatin gene increased muscle strength, according to the 2015 trial report.3
In the 2015 trial, muscle samples after treatment showed less scarring and larger muscle fibres, especially at the higher strength.3
In a 2015 trial, six people with Becker muscular dystrophy received the FS344 gene, carried by an adeno-associated virus. Four walked farther in six minutes afterwards, by 29 to 125 metres, two showed no change, and no adverse effects were reported.3
In a 2017 trial in six people with sporadic inclusion body myositis, walking distance improved by a median of 56 metres a year in treated participants, while eight matched untreated people declined by about 26 metres a year.4
These trials tested a gene therapy, not follistatin protein given directly. The sources reviewed here describe no human study of the protein itself.3,4
Evidence-strength label: Limited human data. How this label is assigned
None of the sources reviewed here reports an approval of follistatin-344 by FDA, as a protein or as a gene therapy.1,6
FDA’s compounding safety-risk page, current as of April 22, 2026, does not list follistatin.6
HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Follistatin-344 is not among them.7,8
Whether the gene-therapy results hold in larger controlled trials: each trial treated six people.3,4
The effects and safety of follistatin protein given directly to people, which the sources reviewed here do not describe.3,5
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Everything PeptideScanner has collected for Follistatin-344: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for Follistatin-344 are a bounded selection, not every registration or paper about Follistatin-344. For the years before Follistatin-344 was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list Follistatin-344 as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name Follistatin-344 in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.
Evidence summary
This profile has no living status brief. Inspect the cited profile records below.
Explore this profile’s cited source records →
An editorial human-evidence summary has not yet been published.
Evidence Map v1
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
0 of 0 selected trial records include at least one phase value; 0 of 0 include a status value in the retained structured contract.
0 of 0 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Research hub
Citations
Numbered markers in the text point here. Each link opens the original public record.
FDA Global Substance Registration System · Official source · Source checked November 16, 2026
Federal Register · Official source · Source checked November 16, 2026
Molecular Therapy · Official source · Source checked November 16, 2026
Molecular Therapy · Official source · Source checked November 16, 2026
Drug Testing and Analysis · Official source · Source checked November 16, 2026
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026